- Home
- CNSY vs PRZO Comparison
CNSY vs PRZO Comparison
Compare CNSY & PRZO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNSY | PRZO |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.6M | 16.9M |
| IPO Year | 2016 | 2022 |
Fundamental Metrics
Financial Performance| Metric | CNSY | PRZO |
|---|---|---|
| Price | $1.31 | $0.52 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $27.75 | N/A |
| AVG Volume (30 Days) | 77.3K | ★ 332.0K |
| Earning Date | 11-17-2026 | 08-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.61 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,213,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $414.61 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.49 | $0.38 |
| 52 Week High | $4.03 | $1.52 |
Technical Indicators
Market Signals| Indicator | CNSY | PRZO |
|---|---|---|
| Relative Strength Index (RSI) | 48.75 | 38.62 |
| Support Level | $1.52 | $0.46 |
| Resistance Level | $2.28 | $0.56 |
| Average True Range (ATR) | 0.16 | 0.04 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 66.67 | 22.12 |
Price Performance
Historical ComparisonAbout CNSY Cerenome Inc. Common Stock
Cerenome Inc is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company's CNSide Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its therapeutic platform, REYOBIQ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation.
About PRZO ParaZero Technologies Ltd.
ParaZero Technologies Ltd operates as an aerospace defense company focused on the development of smart, autonomous solutions for the manned and unmanned aerial systems (UAS) industry. The Company develops, manufactures, markets, and sells counter-UAS net-launching platforms designed to protect against hostile drones in both battlefield and urban environments, precision aerial delivery systems for military applications, and smart, autonomous parachute safety systems designed to enable safe flight operations over populated areas and beyond visual line-of-sight. The Company sells its products internationally.